Stem Cells
Therapies
Stem Cells Therapies
The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China).
FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials.
Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders.
Check the full list of patients who received stem cell therapy derived from FamiCord labs.
List last update: 06.2026
List of patients who received stem cells from FamiCord Group laboratories
| Lp. | Source | Source type | Diagnosis | Medical field | Year of application | Therapy | Country | Age of recipient |
|---|---|---|---|---|---|---|---|---|
| 2501 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 47 |
| 2502 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 29 |
| 2503 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 66 |
| 2504 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 68 |
| 2505 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 40 |
| 2506 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 56 |
| 2507 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 69 |
| 2508 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 59 |
| 2509 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 56 |
| 2510 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 68 |
| 2511 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 66 |
| 2512 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 63 |
| 2513 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 64 |
| 2514 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 64 |
| 2515 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 63 |
| 2516 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 65 |
| 2517 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 68 |
| 2518 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 44 |
| 2519 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 66 |
| 2520 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 48 |
| 2521 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 45 |
| 2522 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 67 |
| 2523 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 69 |
| 2524 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 72 |
| 2525 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 53 |
| 2526 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 71 |
| 2527 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 66 |
| 2528 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 57 |
| 2529 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 74 |
| 2530 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 72 |
| 2531 | Apheresis | Allogeneic | Myelodysplastic Syndrome Lb High Risk | Hematology | 2023 | Standard Therapy | Poland | 58 |
| 2532 | Apheresis | Allogeneic | Myelodysplastic Syndrome With Multilineage Dysplasia | Hematology | 2023 | Standard Therapy | Poland | 68 |
| 2533 | Apheresis | Allogeneic | Myelodysplastic Syndrome/Acute Myelogenous Leukemia | Hematology | 2023 | Standard Therapy | Poland | 42 |
| 2534 | Apheresis | Allogeneic | Myelodysplastic Syndrome-Eb1 | Hematology | 2023 | Standard Therapy | Poland | 48 |
| 2535 | Apheresis | Allogeneic | Myelodysplastic Syndromes (MDS) | Hematology | 2023 | Standard Therapy | Poland | 73 |
| 2536 | Apheresis | Allogeneic | Myelodysplastic Syndromes (MDS) | Hematology | 2023 | Standard Therapy | Poland | 76 |
| 2537 | Apheresis | Allogeneic | Myelodysplastic Syndromes (MDS) | Hematology | 2023 | Standard Therapy | Poland | 70 |
| 2538 | Apheresis | Allogeneic | Myelodysplastic Syndromes (MDS) | Hematology | 2023 | Standard Therapy | Poland | 5 |
| 2539 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2023 | Standard Therapy | Poland | 65 |
| 2540 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2023 | Standard Therapy | Poland | 56 |
| 2541 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2023 | Standard Therapy | Poland | 70 |
| 2542 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2023 | Standard Therapy | Poland | 69 |
| 2543 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2023 | Standard Therapy | Poland | 61 |
| 2544 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2023 | Standard Therapy | Poland | 70 |
| 2545 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2023 | Standard Therapy | Poland | 68 |
| 2546 | Apheresis | Allogeneic | Myelofibrosis Myeloid Metaplasia | Hematology | 2023 | Standard Therapy | Poland | 50 |
| 2547 | Apheresis | Allogeneic | Myelofibrosis Myeloid Metaplasia | Hematology | 2023 | Standard Therapy | Poland | 54 |
| 2548 | Apheresis | Allogeneic | Myelofibrosis Myeloid Metaplasia | Hematology | 2023 | Standard Therapy | Poland | 60 |
| 2549 | Apheresis | Allogeneic | Myeloma Multiplex | Hematology | 2023 | Standard Therapy | Poland | 63 |
| 2550 | Apheresis | Autologous | No Data | Hematology | 2023 | Standard Therapy | Germany | 69 |
| 2551 | Apheresis | Autologous | No Data | Hematology | 2023 | Standard Therapy | Germany | 53 |
| 2552 | Apheresis | Allogeneic | No Data | Hematology | 2023 | Standard Therapy | Poland | 50 |
| 2553 | Apheresis | Allogeneic | No Data | Hematology | 2023 | Standard Therapy | Poland | 23 |
| 2554 | Apheresis | Allogeneic | No Data | Hematology | 2023 | Standard Therapy | Poland | 39 |
| 2555 | Apheresis | Allogeneic | No Data | Hematology | 2023 | Standard Therapy | Poland | 2 |
| 2556 | Apheresis | Allogeneic | No Data | Hematology | 2023 | Standard Therapy | Poland | 52 |
| 2557 | Apheresis | Allogeneic | No Data | Hematology | 2023 | Standard Therapy | Poland | 61 |
| 2558 | Apheresis | Autologous | No Data | Hematology | 2023 | Standard Therapy | Germany | 60 |
| 2559 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2023 | Standard Therapy | Poland | 71 |
| 2560 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2023 | Standard Therapy | Poland | 44 |
| 2561 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2023 | Standard Therapy | Poland | 72 |
| 2562 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2023 | Standard Therapy | Poland | 66 |
| 2563 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2023 | Standard Therapy | Poland | 33 |
| 2564 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2023 | Standard Therapy | Poland | 42 |
| 2565 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2023 | Standard Therapy | Poland | 63 |
| 2566 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2023 | Standard Therapy | Poland | 19 |
| 2567 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2023 | Standard Therapy | Poland | 54 |
| 2568 | Apheresis | Autologous | Nonseminoma, Relapse | Hematology | 2023 | Standard Therapy | Germany | 48 |
| 2569 | Apheresis | Allogeneic | Orofacial Myofunctional Disorders (OMDS), Primary Myelofibrosis (PMF) | Hematology | 2023 | Standard Therapy | Poland | 69 |
| 2570 | Apheresis | Allogeneic | Osteomyelofibrosis | Hematology | 2023 | Standard Therapy | Poland | 60 |
| 2571 | Apheresis | Allogeneic | Other Immune System | Hematology | 2023 | Standard Therapy | Poland | 71 |
| 2572 | Apheresis | Allogeneic | Other Malignancy | Hematology | 2023 | Standard Therapy | Poland | 49 |
| 2573 | Apheresis | Allogeneic | Other Myelofibrosis | Hematology | 2023 | Standard Therapy | Poland | 56 |
| 2574 | Apheresis | Allogeneic | Other Non-Malignant Disease | Hematology | 2023 | Standard Therapy | Poland | 70 |
| 2575 | Apheresis | Allogeneic | Paroxysmal Nocturnal Hemoglobinuria (Pnh) | Hematology | 2023 | Standard Therapy | Poland | 36 |
| 2576 | Apheresis | Allogeneic | Peripheral T-Cell Lymphoma | Hematology | 2023 | Standard Therapy | Poland | 47 |
| 2577 | Apheresis | Autologous | Plasma Cell Leukemia | Hematology | 2023 | Standard Therapy | Germany | 70 |
| 2578 | Apheresis | Autologous | Plasma Cell Leukemia | Hematology | 2023 | Standard Therapy | Germany | 56 |
| 2579 | Apheresis | Autologous | Plasmacytoma | Hematology | 2023 | Standard Therapy | Germany | 63 |
| 2580 | Apheresis | Allogeneic | Post Therapeutic Myelodysplastic Syndrome /Acute Myelogenous Leukemia After Chronic Lymphocytic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 60 |
| 2581 | Apheresis | Allogeneic | Post–Polycythemia Vera Myelofibrosis | Hematology | 2023 | Standard Therapy | Poland | 38 |
| 2582 | Apheresis | Allogeneic | Pra B-Cell Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 20 |
| 2583 | Apheresis | Allogeneic | Pre-B-Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 41 |
| 2584 | Apheresis | Allogeneic | Pre-B-Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 61 |
| 2585 | Apheresis | Allogeneic | Pre-B-Acute Myelogenous Leukemia | Hematology | 2023 | Standard Therapy | Poland | 11 |
| 2586 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2023 | Standard Therapy | Germany | 63 |
| 2587 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2023 | Standard Therapy | Germany | 73 |
| 2588 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2023 | Standard Therapy | Germany | 70 |
| 2589 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2023 | Standard Therapy | Poland | 68 |
| 2590 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2023 | Standard Therapy | Poland | 68 |
| 2591 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2023 | Standard Therapy | Poland | 31 |
| 2592 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2023 | Standard Therapy | Poland | 63 |
| 2593 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2023 | Standard Therapy | Germany | 46 |
| 2594 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2023 | Standard Therapy | Poland | 68 |
| 2595 | Apheresis | Allogeneic | Relapsed B-Cell Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 11 |
| 2596 | Apheresis | Allogeneic | Secondary Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 55 |
| 2597 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2023 | Standard Therapy | Poland | 58 |
| 2598 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2023 | Standard Therapy | Poland | 36 |
| 2599 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2023 | Standard Therapy | Poland | 62 |
| 2600 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2023 | Standard Therapy | Poland | 9 |